SIX MONTHS SAFETY OF A VERO-CELL CULTURE DERIVED JAPANESE ENCEPHALITIS VACCINE, IC51, ACROSS PHASE 3 TRIALS AND IN A LONG-TERM FOLLOW-UP COHORT

被引：0
|
作者：
Dubischar-Kastner, Katrin [1 ]
机构：
[1] Intercell AG, Vienna, Austria
来源：
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2008年 / 79卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
836
引用
收藏
页码：247 / 247
页数：1
相关论文
共 16 条
  • [1] Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO® (IC51), in 6 months of follow-up
    Dubischar-Kastner, Katrin
    Kaltenboeck, Astrid
    Klingler, Anton
    Jilma, Bernd
    Schuller, Elisabeth
    VACCINE, 2010, 28 (39) : 6463 - 6469
  • [2] KINETICS OF THE NEUTRALIZING ANTIBODY RESPONSE TO THE VERO-CELL CULTURE DERIVED JAPANESE ENCEPHALITIS VACCINE, IC51
    Dubischar-Kastner, Katrin
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 79 (06): : 267 - 268
  • [3] Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study
    Schuller, E.
    Jilma, B.
    Voicu, V.
    Golor, G.
    Kollaritsch, H.
    Kaltenboeck, A.
    Klade, C.
    Tauber, E.
    VACCINE, 2008, 26 (34) : 4382 - 4386
  • [4] Immunogenicity and safety of Vero cell culture-derived Japanese encephalitis vaccine: a phase 3 study in Chinese infants
    Wang, Huanhuan
    Wang, Juan
    Yan, Shijie
    Zhao, Gengfan
    Wang, Shanzhen
    Tao, Hong
    Xu, Ye
    Wu, Jinfeng
    EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 958 - 965
  • [5] Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study
    Kaltenboeck, A.
    Dubischar-Kastner, K.
    Eder, G.
    Jilg, W.
    Klade, C.
    Kollaritsch, H.
    Paulke-Korinek, M.
    von Sonnenburg, F.
    Spruth, M.
    Tauber, E.
    Wiedermann, U.
    Schuller, E.
    VACCINE, 2009, 27 (33) : 4483 - 4489
  • [6] Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine
    Yun, Ki Wook
    Lee, Hoan Jong
    Park, Ji Young
    Cho, Hye-Kyung
    Kim, Yae-Jean
    Kim, Kyung-Hyo
    Kim, Nam Hee
    Hong, Young Jin
    Kim, Dong Ho
    Kim, Hwang Min
    Cha, Sung-Ho
    VACCINE, 2018, 36 (11) : 1398 - 1404
  • [7] Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
    Ngoc Huu Tran
    Chansinghakul, Danaya
    Chong, Chia Yin
    Low, Chian Yong
    Shek, Lynette P.
    Chan Quang Luong
    Fargo, Carina
    Wartel, T. Anh
    Sun, Sunny
    Skipetrova, Anna
    Bouckenooghe, Alain
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (10) : 2315 - 2327
  • [8] Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls Three-year Follow-up of a Randomized Phase III Trial
    Lin, Lan
    Macias Parra, Mercedes
    Sierra, Victor Y.
    Salas Cespedes, Albino
    Granados, Maria Angelica
    Luque, Adriana
    Karkada, Naveen
    Castrejon Alba, Maria Mercedes
    Romano-Mazzotti, Luis
    Borys, Dorota
    Struyf, Frank
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (10) : 1061 - 1067
  • [9] Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
    Kim, Min Jung
    Park, Eun Hye
    Shin, Kichul
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3566 - 3567
  • [10] Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials (vol 15, pg 2315, 2019)
    Ngoc Huu Tran
    Chansinghakul, Danaya
    Chong, Chia Yin
    Low, Chian Yong
    Shek, Lynette P.
    Chan Quang Luong
    Frago, Carina
    Wartel, T. Anh
    Sun, Sunny
    Skipetrova, Anna
    Bouckenooghe, Alain
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (06) : 1877 - 1877
12